期刊
HUMAN PSYCHOPHARMACOLOGY-CLINICAL AND EXPERIMENTAL
卷 24, 期 2, 页码 135-143出版社
WILEY
DOI: 10.1002/hup.1001
关键词
major depressive disorder; weight gain; atypical antipsychotics; augmentation
资金
- Ministry of health, welfare and family affairs, Republic of Korea [A050047]
Objective The extent of weight changes in depressed patients who use atypical antipsychotics (AAP) as augmentation could not be easily predicted due to weight related symptoms of depression and the interaction with antidepressants which have weigh(reducing effects. Methods Patients were treated with either antidepressants augmented with AAP for more than 2 weeks (AAP group, n = 100) or Only with antidepressants (non-AAP group, n = 172) during the admission between 2002 and 2006, and the differences in weight were analyzed. Results Mean weight gains of AAP group were significantly higher than those of non-AAP group (2.98 +/- 1.87 kg vs. 1.70 +/- 1.85 kg, p = 0.001). When stratified by antidepressants, the significant difference between the two groups was shown among the subjects who had taken serotonin reuptake inhibitors (SSRIs), but not mirtazapine and venlafaxine (3.42 +/- 2.01 kg vs. 1.48 +/- 1.79 kg, p < 0.00 1). Comparing among different combinations in AAP group showed that subjects treated with SSRIs and olanzapine had the greatest weight gain (4.21 +/- 1.90 kg), significantly higher than that of the other subgroups (P < 0.001). Conclusions Our findings suggest that AAP used inpatients with depression could severely aggravate preexisting weight-related problems of antidepressants use and the possibility that the combined use with specific antidepressants could have a unique effect on weight by drug-drug interactions. Copyright (C) 2009 John Wiley & Sons, Ltd.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据